AngioDynamics (ANGO) announced the publication of results from the PRESERVE study in the journal European Urology. The study assessed the safety and effectiveness of irreversible electroporation with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer. The study met its primary effectiveness endpoint, with 84% of men free from in-field, clinically significant disease at 12 months.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics’ Strong FY25 Performance and Optimistic FY26 Outlook Support Buy Rating
- AngioDynamics initiated with a Buy at Lake Street
- AngioDynamics price target raised to $17 from $15 at Canaccord
- AngioDynamics Reports Strong Growth in Fiscal 2025
- AngioDynamics Reports Strong Growth Amid Challenges